0,rehospitalization
1,admissions
2,4-year survival
3,median
4,acetyltransferases
5,denervation
6,pharmaceuticals
7,transoesophageal
8,meta-analysis
9,lean mass index
10,time span
11,non-randomized
12,hazard ratios
13,chf
14,abstract
15,baroreflex
16,observational study
17,etidronate
18,non-aas
19,relative wall thickness
20,propensity-score
21,diagnostic
22,randomized trial
23,cardiac magnetic resonance
24,distressing
25,rvpo
26,left atrium
27,myocyte
28,reducing
29,biventricular
30,tactics
31,2-vessel
32,bcl-2
33,air pollution
34,postsystolic function
35,functional status
36,anti-neoplastic
37,pressure-volume
38,placebo-controlled
39,ref
40,health
41,co-morbidity
42,interpretation
43,systematic review
44,congenital lesions
45,infarction
46,afterload
47,endothelial-protective
48,evidence-based treatments
49,objectives
50,hf-induced
51,long-term prognosis
52,muscle-wasting
53,voltage-gated
54,mass correlated
55,euthanization
56,system blocker
57,endoplasmic reticulum
58,prognostic factor
59,subclinical
60,health-care
61,fibrillation
62,rotor
63,adenosine
64,partial reduction
65,predictor
66,therapeutics
67,recreational
68,cardiomyocytes
69,potential benefits
70,partial attenuation
71,biological phenotype
72,goal-directed lipid-lowering
73,advanced heart failure
74,sex-matched
75,peak oxygen
76,fluid retention
77,improved survival
78,loss of fat
79,tobacco
80,atrial fibrillation
81,linear mixed
82,proportional
83,nonmitochondrial
84,modest reduction
85,left-to-right
86,correction
87,patient-level regression
88,underperfusion
89,improved ventricular-arterial coupling
90,hhd
91,attrition
92,pathway changes
93,12-lead
94,blockers
95,stimulation
96,practice-level
97,relative
98,two-center
99,mechanical
100,velocity
101,high-sensitivity
102,explant
103,myoctyes
104,np
105,conditioning
106,post-translational
107,decrement
108,carcinoma
109,lean zsf1
110,centers
111,defibrillator
112,levels
113,hf prediction
114,extrapolating
115,lcx
116,pulseless
117,individualized approaches
118,biomedical
119,pathway
120,oht
121,free mass
122,sst2 concentrations
123,muscle mass
124,moderate-intensity
125,abdominal
126,aforementioned
127,secondary end points
128,post-myocardial
129,ischemic-hypertensive
130,proof-of-principle
131,3.5 g
132,periprocedural
133,mass ratio
134,diastolic
135,crf
136,pressure-overload-induced hypertrophy
137,cytoskeletal
138,deals
139,stiffness
140,follow-up
141,sodium-restricted
142,midpapillary
143,full-length scn5a
144,superfamily
145,treatment
146,hypophosphorylation
147,myosin
148,transgenic mice
149,egfr
150,surgical ring
151,congestion-like
152,left ventricular ejection
153,sternotomy
154,per sd
155,unloading
156,main effect
157,electrocardiographic
158,discrepancy
159,refill
160,internal diameter
161,guideline
162,contractile response
163,guiding
164,extubated
165,exogenous
166,titrated
167,erasers
168,random-effects
169,left ventricular tissue
170,beneficial effects
171,individualized assessment
172,2-erk1
173,β-blocker
174,exponent
175,pyridostigmine
176,context
177,modestly
178,ischemic
179,end-diastolic
180,evidence gaps
181,therapy
182,adenylyl cyclase
183,single-cohort
184,germline
185,osprey
186,feet
187,control
188,alendronate
189,elevated
190,transfusion
191,black race
192,activated
193,fraction
194,turned on
195,clinical setting
196,protocol-driven
197,hfref
198,channelopathies
199,level of epithelial
200,hazard ratio
201,cardiorespiratory
202,mass spectrometric
203,muscle strips
204,ejection
205,hemolysis
206,downstream signalling
207,carvedilol
208,anastomosis
209,clinical prediction
210,developmental chromatin
211,6-month mortality
212,importance
213,unfolded
214,derangement
215,home
216,blood testing
217,triggers
218,decreases
219,clinical trials-enriching
220,transition markers
221,maladaptive
222,inotropes
223,out-patient
224,age-specific
225,transient receptor potential
226,randomised
227,cardiomyopathy
228,free-breathing
229,self-care
230,adult population
231,mr
232,reliability
233,cross-sectional
234,left
235,end-systolic
236,periprocedural deaths
237,collect
238,uneventful recovery
239,speckle tracking
240,permeability
241,methylatropine
242,pressure
243,pre-post
244,markers
245,amyloidosis
246,tolerated
247,feeding
248,into the statistical model
249,left bundle
250,fluctuations
251,post-hct
252,non-cachectic
253,anaerobic
254,descriptive statistics
255,eligibility
256,cardiac angiogenesis
257,bcl2
258,avoidance
259,conscious
260,baseline hrqol
261,rv
262,ip
263,delay
264,activation
265,rounds
266,noninvasive
267,consumption
268,analyses
269,clinical data
270,sympathovagal
271,hospital length
272,system inhibitors
273,cgmp
274,raloxifene
275,endopeptidase
276,nontreatment
277,adjusted hazard ratio
278,chemotherapy
279,long-acting
280,shortcomings
281,life-sustaining
282,short-term mortality
283,right-sided
284,heart rate variation
285,higher-than-expected
286,ventricular
287,logistic regression
288,blood loss
289,advanced copd
290,beta-blocker
291,congenital
292,all-cause
293,echocardiographic
294,candesartan
295,myocytes
296,tachyarrhythmias
297,breath-holding
298,interaction
299,hospitalization
300,delayed
301,randomization
302,left ventricular
303,signaling
304,heart rate
305,activate
306,comparisons
307,analysis
308,valve
309,induced recovery
310,splicing
311,coated
312,re-activating
313,echo-doppler
314,uptake
315,weight loss
316,downward regression
317,isoforms
318,weak
319,incubated
320,e'lateral
321,spite
322,halts
323,hhf
324,warranted
325,young adult
326,change
327,inhibitory
328,consumption rate
329,white
330,hgb
331,stand-alone
332,peptides
333,differential effect
334,noncoding
335,percutaneous coronary
336,cpcs
337,deacetylases
338,normalization
339,doppler
340,cross-linking
341,heart failure-related
342,on hdl
343,yields
344,resistance
345,independent predictors
346,chelation
347,taxonomy
348,management of gastrointestinal bleeding
349,shortens
350,risk-standardized mortality
351,exerted
352,resting hemodynamics
353,adherence
354,course
355,icu
356,sheet orientation
357,subtle changes
358,outpatient setting
359,embolectomy
360,catheterization
361,circulating
362,schfi
363,sequential phosphorylation
364,nbdmards
365,right ventricle
366,elevated sympathetic
367,evidence-based therapies
368,future perspectives
369,health-related
370,downward
371,enrolled
372,flow-mediated dilatation diameter
373,co-morbidities
374,viscoelastic
375,behavioural-change
376,acute
377,proangiogenic
378,(-)-epicatechin-rich
379,engage
380,renin-angiotensin
381,parallel-group
382,events
383,financial incentives
384,acute kidney
385,thromboembolic
386,collinearity
387,pump
388,per capita
389,senescence
390,reversal
391,power
392,length of follow-up
393,nanomolar
394,nontrastuzumab
395,valvular
396,power index
397,transverse aortic constriction
398,instability
399,telephone support
400,index admission
401,timed
402,precapillary
403,canine electromechanics
404,biomarker
405,test-retest
406,monitoring
407,deciles
408,underwent prospective
409,renal
410,tachycardia
411,mass index
412,clinical variables
413,therapeutic
414,endpoint
415,well-being
416,ros
417,adoption
418,twist
419,anthracycline-induced
420,peptide
421,thirty-seven
422,thromboembolism
423,hypertrophy
424,transition
425,tests
426,congenital abnormalities
427,growth
428,ffm
429,nervous system
430,post-acute
431,postoperatively
432,rotation
433,aged
434,cpgs
435,beta blockers
436,confidence interval
437,reclassification
438,risk reduction
439,well-treated
440,signalosome
441,fatty acids
442,dl
443,atropine
444,aldosterone
445,undertaken
446,pre-hct
447,deactivation
448,biomarker-guided
449,serum factors
450,leg strength
451,metabolism
452,monoclonal
453,ecct
454,ischaemia
455,accounting
456,high-quality
457,northwest
458,diet adherence
459,doxorubicin-induced
460,on renal function
461,whites
462,myocyte diameter
463,lean mass
464,severe hypertension
465,arthritis
466,peripheral
467,nontraumatic
468,inactive
469,writer
470,longitudinal performance
471,serum
472,pathogenesis
473,practice settings
474,admission
475,remarkable
476,unchanged
477,perioperative
478,clinical benefit
479,tug
480,clin
481,cardiology
482,exploratory factor
483,hypertension
484,cells
485,antihyperglycemic
486,exhaustion
487,tonometry
488,electron microscopy
489,endothelial function
490,leaflet
491,end-of-life
492,tricuspid annular plane
493,gadolinium-chelate
494,heart failure mortality
495,mapping
496,functional enrichment
497,shunts
498,level of agreement
499,conduction
500,longitudinal
501,strengths
502,atherosclerosis
503,hemodynamic
504,radiation
505,methotrexate
506,altered
507,actin
508,nonadherence
509,canine
510,end-stage
511,advanced hf
512,ventricular mass
513,norepinephrine-induced
514,icds
515,explants
516,mo
517,changes
518,post-lvad
519,two-vessel
520,secretion
521,body mass index
522,retrospective
523,kappa coefficients
524,inotropic effect
525,pump failure
526,foundation
527,eplerenone
528,haematopoietic
529,electric
530,protective
531,energy substrate
532,pharmaceutically
533,overweight
534,atrium
535,cytochrome
536,dynamic
537,bromodomain
538,progressive
539,hgb level
540,right heart
541,ami
542,perfusion
543,decoy
544,time-limited
545,angioplasty
546,doctors
547,relative reduction
548,reports
549,acute care
550,humanized
551,cardiotoxicity
552,networks
553,infarction-related
554,atherosclerotic
555,into the pathophysiology
556,hm
557,psss
558,induced pluripotent stem cell-derived
559,α-subunit
560,association
561,urea nitrogen
562,ml
563,lesions
564,quality-of-life
565,brachial
566,cardiovascular
567,trichrome
568,inability
569,resting
570,dd
571,all-cause hospitalizations
572,velocities
573,infusions
574,secondary
575,interatrial shunting
576,subpulmonary ventricle
577,pure epicatechin
578,sympathetic nervous
579,xo
580,beta blockade
581,contrast
582,natriuretic peptides
583,peak respiratory
584,uptitration
585,baseline
586,forward
587,altered ventricular
588,cardiopulmonary
589,responsiveness
590,conscious rabbits
591,s'lateral
592,elevations
593,norepinephrine
594,treadmill
595,nonselective
596,effectiveness
597,pathological stress
598,inotropic
599,shunt
600,nondiabetic
601,throughput
602,cost-minimization
603,aac
604,confounders
605,overview
606,dogs
607,fiber
608,testing
609,left-hand
610,slowness
611,proportional hazards
612,pde2
613,young
614,hdl-mediated
615,atrial pressure
616,action potentials
617,profound change
618,rabbits
619,likelihood ratio
620,oxygen
621,ras
622,diuretic refractory
623,collagen
624,renin-angiotensin-aldosterone
625,followed-up
626,prescriptive
627,icd
628,beyond the cardiovascular system
629,relative decrease
630,lifesaving
631,side effects
632,caloric
633,regression
634,expenditure
635,etiologic
636,thrombosis
637,dearth
638,subgroups
639,transseptal catheterisation
640,calreticulin
641,long-term outcomes
642,ivabradine-treated
643,sepsis
644,overexpression
645,energy expenditure
646,atheromatous
647,in pigs
648,time-varying
649,transduction cascade
650,hypotension
651,quality of life
652,basal
653,cornerstone
654,tolvaptan
655,cell yield
656,health care
657,erythropoiesis-stimulating
658,acetyltransferase
659,magnetic resonance
660,breast
661,vagal tone
662,effector
663,xo-mediated
664,undergoing
665,nitroxyl
666,sudden death
667,depresses
668,subunits
669,hno
670,intolerance
671,matched-pairs
672,bypass
673,metric
674,mutant mice
675,growth factor-β
676,irs1
677,systolic ventricular
678,preoperative renal
679,intima-media thickness
680,α-myosin
681,endothelin
682,pf
683,amplitude
684,self-identified
685,biopsy
686,care transfer
687,qt
688,bets
689,responsive
690,observational cohort
691,shorter
692,tomographic angiography
693,trends
694,measurements
695,inpatient admissions
696,long-term
697,risk factor
698,10-eo-cfu
699,postoperative
700,functions
701,therapeutic implications
702,myocardial
703,pressure gradient
704,beta-blockers
705,emotional stress
706,looping
707,statistical significance
708,extending
709,pulse-wave velocity
710,driven
711,threefold increase
712,echocardiograms
713,pathological hypertrophy
714,electromechanical
715,congenital heart lesions
716,camp-dependent
717,covariates
718,heart dilatation
719,enhancement imaging
720,hf-related
721,insertion
722,electronic databases
723,growth factor
724,risk factors
725,classified
726,enhanced hemocompatibility
727,readmission reduction
728,trials
729,altered expression
730,heartmate
731,myocyte-specific
732,advanced
733,platelet-activating factor
734,2-fold
735,time-domain
736,normal geometry
737,procedures
738,independent predictor
739,subdomains
740,bpm
741,covariate
742,catheter
743,anesthetized
744,beta-adrenergic
745,infarction-both
746,normalized
747,carbohydrates
748,angiotensin-converting
749,yielded
750,substitution
751,exacerbated
752,relaxation
753,myocardial fibrosis
754,high mortality
755,non-diastolic
756,initial approach
757,reference data
758,human ventricular systolic
759,cyclic
760,high-risk
761,event profile
762,systolic
763,conventional surgery
764,filling
765,crt
766,pneumonia
767,long-term support
768,apex
769,oxygenation membrane
770,treatments
771,guideline-recommended
772,on the timing
773,basal rotations
774,diuretic effect
775,signalling
776,s'septal
777,dilatation
778,absorption
779,natriuretic peptide
780,m2
781,hearts
782,2 signalling
783,stretch rate
784,hospital admission
785,slope
786,surgical
787,vasopressin
788,post-translational state
789,borderline
790,ans
791,multimarker-based
792,depressed
793,vad
794,histological
795,extracellular matrix
796,parasympathetic
797,muscles
798,real-world setting
799,on the clinical response
800,geometry
801,branch
802,obstructed
803,on the composite
804,grading
805,collateral growth
806,infusion
807,underlying
808,3-vessel
809,noncardiologist
810,non-sudden
811,2+)-pump
812,beat
813,single-payer
814,early deaths
815,qol
816,ultrasonography
817,stimuli
818,wasting
819,mistargeting
820,evaluable
821,unloads
822,tachypacing-induced
823,relationship
824,factorial trial
825,atrial area
826,left ventricular systolic
827,downregulation
828,full potential
829,statistical
830,lability
831,defibrillators
832,high-volume
833,non-hf
834,ankle-brachial index
835,infancy
836,camp
837,myocardial changes
838,rest
839,retrieved
840,3.5-fold
841,clinical trial
842,end points
843,first-in-man
844,histologically
845,ages
846,right ventricular
847,brief hypothermic
848,induced
849,right coronary artery
850,adjustment
851,study design
852,relative risk
853,trigger
854,tension
855,single-centre
856,cava
857,overload
858,channels
859,change in distribution
860,mice
861,channel-dependent
862,wall stress
863,single-institution
864,reverse
865,training
866,lb
867,electrocardiographers
868,transmitral
869,lad
870,low-volume
871,resynchronization
872,cytoskeleton
873,general anaesthesia
874,oxygenation
875,intermuscular fat ratio
876,morphology
877,end stage
878,impact of rm
879,late-onset
880,bradyarrhythmias
881,chest
882,body composition
883,p38alpha
884,primary isolated
885,electrical activation
886,long time
887,sequence-specific
888,hospitals
889,decreased expression
890,relevance
891,transcription factors
892,aging
893,theory
894,sodium restriction
895,haemodynamic stress
896,intermediate care
897,interplay
898,caspase-3
899,myocyte differentiation
900,2+)-uptake
901,second-generation sulfonylureas
902,beginning
903,faster turnaround
904,linear pathway
905,time of surgery
906,adenoviral
907,e'septal
908,polymorphism
909,basal contractility
910,case-fatality
911,washout
912,blood transfusions
913,recorded mortality
914,indeterminable
915,vehicle-treated rats
916,eseptal
917,placebo-treated
918,regimen
919,impairment
920,gg
921,unanchors titin
922,adjunctive
923,network
924,conditional gene-targeted
925,dynamics
926,length of stay
927,matched
928,evidence-based
929,exerts
930,practice-level differences
931,sample
932,tricuspid
933,diet
934,post-transplant mortality
935,elicited
936,all-cause hospitalization
937,magnetic resonance angiography
938,loading
939,coupling
940,glycolysis
941,reduction
942,neonatal
943,per se
944,radial strain
945,clinical care
946,end-systole
947,tracked
948,hand-searching
949,venoarterial dilation
950,angiogenesis
951,oscillatory ventilation
952,eo-cfus
953,health system
954,flow
955,long-term effects
956,halt
957,ameliorates
958,systemic vascular resistance
959,cost of the intervention
960,p70s6k-ser
961,device-related
962,hfpef
963,standardized
964,myocardial phosphodiesterase-2
965,transgenic
966,length
967,splice
968,t1
969,overexpressing
970,up-regulated
971,control group
972,receptor
973,angina
974,pronounced
975,outflow
976,arrhythmia
977,arrhythmias
978,intake
979,pharmacologic
980,drive
981,limitation
982,signed-rank
983,low-frequency
984,downstream signaling
985,expansion
986,hfvt(-)
987,extended
988,patterning
989,pro-adrenomedullin
990,age group
991,first-ever
992,myocardial glycolysis
993,environment
994,expenditures
995,with.estimates
996,heart magnetic resonance imaging
997,functional
998,atrial
999,conduction abnormalities
1000,volume
1001,systole
1002,high-strength
1003,readmission
1004,venous thromboembolic
1005,mechanism
1006,post-dash
1007,analyzed
1008,paradigm shift
1009,managing
1010,absorptiometry
1011,currents
1012,overstimulation
1013,pef
1014,postoperative mortality
1015,collected
1016,camp production
1017,lbbb
1018,technology
1019,lean body mass
1020,pg
1021,validity
1022,arm cuff
1023,external validity
1024,concentrations
1025,uninephrectomy
1026,ejection fraction
1027,intubated
1028,time of admission
1029,low-dose
1030,purpose of review
1031,post-tac
1032,refractory
1033,pacing-induced
1034,pulse
1035,2.5 kg
1036,rrna
1037,radiological
1038,icd-hf
1039,contact
1040,non-linear
1041,surrogates
1042,subunit
1043,conductance
1044,peripheral vascular
1045,antiplatelet
1046,rhythm
1047,underwent catheterization
1048,mechanical circulatory
1049,intubations
1050,free wall
1051,bioenergetics
1052,allopurinol
1053,blood pressure
1054,hscrp
1055,etiologies
1056,recruitment
1057,first-in-class inhibitor
1058,poor prognosis
1059,extracorporeal
1060,exercise-induced
1061,capability
1062,cardiac-resynchronization
1063,primary care
1064,per cent
1065,embolism
1066,pulse sequence
1067,single-center
1068,correlated
1069,devices
1070,step
1071,inhibitor
1072,angiotensin-aldosterone
1073,hemodynamically
1074,stenosis
1075,inverse
1076,high-frequency
1077,major branches
1078,data sources
1079,exercise
1080,controlled trial
1081,myxoma
1082,outpatients
1083,anthracycline-treated breast
1084,grip
1085,breathlessness
1086,heart
1087,hospital mortality
1088,confounding
1089,aetiologies
1090,ischemia
1091,primary endpoint
1092,rheumatoid
1093,single-arm
1094,potent inhibition
1095,long-term mortality
1096,awful
1097,per week
1098,resonance
1099,myofibre
1100,coprimary
1101,randomized
1102,discharge
1103,stressors
1104,clinical diastolic
1105,stenotic physiology
1106,pairwise
1107,upregulated
1108,dithiothreitol
1109,review
1110,bridge
1111,4-fold
1112,sympathetic
1113,resistant hypertension
1114,pacing
1115,hospitalizations
1116,center
1117,physical exertion
1118,triangular resection
1119,blood flow
1120,glomerular
1121,high-cost
1122,self-rated depression
1123,dipeptidyl
1124,extracellular flux analyzer
1125,c-kit
1126,tube
1127,underlie
1128,haplotype
1129,elderly
1130,evolution
1131,bleeding
1132,work rate
1133,briefing
1134,vt
1135,outcome-monitoring
1136,on the raas
1137,restored β-ar
1138,forty-six
1139,thrombotic
1140,internal consistency
1141,overexpress
1142,transfusions
1143,induction
1144,left atrial pressure
1145,raloxifene-treated
1146,propensity score-matched
1147,atrial pacing
1148,cardiology-cardiovascular
1149,microarray
1150,end of life
1151,hypokalemia
1152,large-scale
1153,controls
1154,benefit
1155,stent
1156,interventions
1157,methodology
1158,outline
1159,function
1160,mapped
1161,upstream signal
1162,sitagliptin
1163,healthcare
1164,contextual
1165,multiple myeloma
1166,prolapse
1167,underlies
1168,hypoalbuminemia
1169,dt
1170,transmitral flow
1171,irs2
1172,enrollment
1173,cardioprotection
1174,pro-brain
1175,lvet
1176,aim
1177,examination
1178,cost-effectiveness
1179,clinical status
1180,noncardiac
1181,net
1182,exchange
1183,exacerbates
1184,background
1185,ultrastructural changes
1186,b-treated
1187,telemonitoring
1188,multivariate
1189,continuity
1190,frame
1191,clear organic lesion
1192,reviewers
1193,economic savings
1194,functional capacity
1195,reduction of sympathetic tone
1196,phospholamban
1197,on hdl-mediated
1198,deranged
1199,tonometric
1200,stress
1201,pathology
1202,cost-effectiveness ratios
1203,double-blind trial
1204,gait therapy
1205,left ventricular filling
1206,adhesion
1207,encoding
1208,infarct
1209,wild-type
1210,extend
1211,to titin
1212,post-pd
1213,venous
1214,myocardium
1215,early-activated
1216,exposed
1217,prevention
1218,multicenter
1219,extracorporeal membrane
1220,turbulence
1221,genotyped
1222,isoproterenol
1223,nitric oxide
1224,adenine
1225,sts
1226,milliseconds
1227,web
1228,large trial
1229,frail
1230,setting
1231,non-ischemic
1232,hg
1233,left heart twist
1234,complexities
1235,hf-ref
1236,neurotransmission
1237,endothelial growth factor
1238,mouse
1239,cost savings
1240,bridged
1241,single parameters
1242,anthracyclines
1243,third trial
1244,pathological
1245,frailty
1246,clinical trials
1247,cardioverter-defibrillators
1248,receptors
1249,mlhf
1250,time of inclusion
1251,magnetic resonance imaging
1252,findings
1253,mrna
1254,research
1255,activity
1256,renin
1257,fatigue
1258,stay
1259,pay-for-performance
1260,objective
1261,iron
1262,lc-ms
1263,postcontrast
1264,oversewing
1265,rise
1266,phosphorylation
1267,radial artery
1268,alter chromatin
1269,exertional
1270,projecting
1271,general linear
1272,mechanisms
1273,6mwt
1274,evolving
1275,hemoglobin
1276,angiography
1277,nonfatal
1278,cardiogenic
1279,phase 2
1280,congestion
1281,heart failure
1282,warrants
1283,transient
1284,active
1285,cost per patient
1286,hypertensive
1287,life expectancy
1288,combined treatment
1289,practices
1290,tachycardia-induced
1291,on mortality
1292,rationale
1293,albeit
1294,spectral
1295,re-hospitalization
1296,ivabradine
1297,community-based
1298,inducible
1299,heart iron
1300,mixed linear
1301,knockdown
1302,10-cell
1303,predict mortality
1304,potassium
1305,food-frequency
1306,dobutamine
1307,differences
1308,infrequent
1309,transduction
1310,overlapped
1311,cyclase
1312,controlled feasibility
1313,interleukin
1314,decongestion
1315,depolarization
1316,subscales
1317,hipsc-cms
1318,i.p.
1319,subvalvular
1320,mutant
1321,liver
1322,pressures
1323,anthracycline
1324,end diameter
1325,regression line
1326,reduced mortality
1327,multisite
1328,general population
1329,hfvt(+)
1330,precipitating factor
1331,all-cause hospitalisations
1332,cutoff point
1333,myocardial angiogenesis
1334,circulatory
1335,life-threatening
1336,thickness
1337,right ventricular pacing
1338,assessment
1339,left ventricular biopsies
1340,lower mortality
1341,pacemakers
1342,fractional area
1343,excursion
1344,defibrillator-only
1345,first week
1346,biomarkers
1347,coagulability
1348,bradycardic
1349,intubation
1350,overwhelming
1351,noted
1352,central glycosylated
1353,attenuated
1354,3.5 mmol
1355,monophosphate
1356,peritoneal dialysis
1357,energy
1358,skinfold thickness
1359,morphological
1360,pathobiology
1361,readers
1362,peripheral muscles
1363,balance
1364,centre
1365,rhythm-control
1366,echocardiography
1367,acs
1368,bridging
1369,risk-adjusted mortality
1370,chemotherapy-induced
1371,few
1372,interactions
1373,die
1374,unaltered
1375,action potential
1376,visit
1377,right ventricular pump
1378,capillary wedge pressure
1379,time interval
1380,readmissions
1381,levels of epinephrine
1382,hepatic
1383,5.5 mmol
1384,cardiac chromatin
1385,event rate
1386,primary outcome
1387,trainings
1388,uncontrolled hypertension
1389,risk prediction
1390,kidney
1391,intervention
1392,msec
1393,content-driven
1394,advanced management
1395,bound
1396,post-translational states
1397,hallmark
1398,electrical activation sequence
1399,walking
1400,length-force
1401,assessed
1402,left ventricle
1403,tachycardic
1404,cytotoxic effect
1405,workload
1406,double-knockout
1407,nps
1408,non-lbbb
1409,postmenopausal
1410,modulates
1411,saf
1412,levels of social support
1413,defibrillator-crt
1414,telehealth
1415,systemic blood pressure
1416,time-dependent covariates
1417,gait
1418,aortic
1419,management
1420,exacerbation
1421,strokes
1422,rate-control
1423,low-quality evidence
1424,progenitor
1425,post
1426,translational repression
1427,immunoprecipitation
1428,authors
1429,non-fatal stroke
1430,sensitivity
1431,underwent
1432,reversed
1433,exertion
1434,trial
1435,acetyl-lysine
1436,lateral wall
1437,cox regression
1438,ckd
1439,practice-level variation
1440,interquartile range
1441,hydrolysis
1442,slower
1443,acute coronary
1444,hand
1445,core
1446,contractility
1447,index
1448,acetylcholinesterase
1449,o2
1450,anthracycline-containing
1451,biopsies
1452,electrical stimulation
1453,altering
1454,biosynthetic
1455,explanted
1456,adaptive
1457,variability
1458,alternative
1459,contextual factors
1460,on the same day
1461,new-user
1462,paced
1463,post-transplant
1464,ablation
1465,left ventricular dilatation
1466,ste
1467,center retrospective
1468,nonsurvivors
1469,cutoff
1470,cardiomyocyte
1471,clinical change
1472,clear evidence
1473,samples
1474,race
1475,all-cause death
1476,dialysis-dependent
1477,harms
1478,3-year mortality
1479,monocytes
1480,young athletes
1481,outpatient settings
1482,inhospital mortality
1483,sst2
1484,flow velocity
1485,embryonic kidney
1486,detectable change
1487,lusitropic
1488,breathing
1489,hct
1490,assays
1491,abnormalities
1492,nurse
1493,mir-25
1494,early-onset
1495,drawn
1496,2 trials
1497,observational studies
1498,resynthesis
1499,new-onset
1500,effective arterial elastance
1501,high-fat
1502,leading
1503,cohorts
1504,per os
1505,ventricular wall stress
1506,clinical outcomes
1507,energy production
1508,clinical practice
1509,angiotensin-receptor
1510,intermediate
1511,isoenzymes
1512,pathophysiology
1513,pathophysiological
1514,peak quadriceps
1515,assay
1516,surrogate
1517,control adenovirus
1518,meta-analyzed mortality
1519,control model
1520,histologic
1521,renin-angiotensin-aldosteron
1522,kappa coefficient
1523,diuretic
1524,non-invasively
1525,post hoc
1526,double mutant
1527,furosemide
1528,radial
1529,connection
1530,myocardial tissues
1531,doxorubicin
1532,allogeneic
1533,long-term survival
1534,8-fluo-camp
1535,myofibrillar
1536,endpoints
1537,explant-derived
1538,endothelial dysfunction
1539,pressure-overload
1540,statistic
1541,blood-flow
1542,bromodomain-containing
1543,leaflet resection
1544,impaired
1545,ventricularly
1546,assembly
1547,atrioventricular
1548,guidelines
1549,closure
1550,duration of antiplatelet
1551,noncardiovascular
1552,pioglitazone
1553,postnatal
1554,heavy chain
1555,inputs
1556,high-density
1557,21 beagle
1558,emission
1559,hypertrophic
1560,large trials
1561,cost analysis
1562,hretn
1563,via detergent
1564,hospitalisations
1565,myocarditis
1566,synchrony
1567,abrogate
1568,experimental
1569,pressure response
1570,preoperative renal dysfunction
1571,protocol
1572,pathological heart
1573,waist circumference
1574,cardioverter
1575,visits
1576,imaging
1577,embryonic
1578,pathways
1579,middle-aged
1580,sub-sample
1581,nephrectomy
1582,tethering
1583,beneficial effect
1584,flow velocities
1585,bioprosthetic
1586,activators
1587,transitions
1588,case-control
1589,inroads
1590,erc
1591,right ventricular pressure
1592,right ventricular-pulmonary
1593,hyperkalemia
1594,transcatheter
1595,fixed ring size
1596,spironolactone
1597,gating
1598,trans
1599,analyze
1600,resistin
1601,double-blind
1602,therapeutic potential
1603,baseline hgb
1604,infarcted
1605,sudden
1606,inhibitors
1607,capillary
1608,joint effect
1609,off-pump
1610,degenerative
1611,computed
1612,died
1613,cardiography
1614,bet
1615,hf
1616,young adults
1617,cm2
1618,mixed-methods
1619,emean
1620,placebo
1621,discharged
1622,blocker
1623,gene expression
1624,subproteomes
1625,etiology
1626,qrs
1627,nbdmard
1628,testosterone
1629,annular size reduction
1630,preoperative
1631,myocardial oxygen
1632,abrogated
1633,shortening
1634,enriched
1635,albumin
1636,downstream
1637,isoprenaline
1638,1.5-t
1639,mitogen-activated
1640,revascularization
1641,nt-probnp
1642,age-by-lvef
1643,angiotensin
1644,abnormal chamber
1645,choline
1646,unsuitable
1647,movement
1648,reducing mortality
1649,nonterminal epitopes
1650,mitral
1651,btt
1652,evidence-based management
1653,poc
1654,pre-participation
1655,curves
1656,downregulated
1657,referrals
1658,short-term
1659,right heart failure
1660,volume index
1661,intensive care
1662,hospital admissions
1663,occlusion
1664,antiarrhythmic
1665,age-matched
1666,fixed-rate
1667,density
1668,partial pressure
1669,test
1670,blunts
1671,anthracycline-related
1672,transduction pathways
1673,early-outgrowth
1674,influx
1675,outpatient
1676,circumflex
1677,wk
1678,laboratory
1679,metoprolol
1680,new therapeutic
1681,embedded
1682,myofilament
1683,university
1684,surgically
1685,technical advisors
1686,sulfonylureas
1687,hyperlipidaemia
1688,add-on diagnostic
1689,haemodynamic
1690,undergoing renal
1691,inflow velocity
1692,anemic
1693,ctnt
1694,tested
1695,hf-action
1696,homeostasis
1697,plasticity
1698,allocation ratio
1699,fm
1700,long-term ventricular
1701,functional efficacy
1702,biological
1703,pb
1704,adult
1705,modality
1706,responses
1707,peripheral edema
1708,sustainability
1709,insulin-resistance
1710,inpatient
1711,myocardial infarction
1712,organ failure
1713,decompensated
1714,nodularity
1715,overlapping
1716,deposition
1717,subcellular
1718,expectancy
1719,bisphosphonates
1720,event-free
1721,walk
1722,dialysis
1723,primary oscillations
1724,randomised-controlled
1725,bundle-branch
1726,regurgitation
1727,diuretics
1728,measuring
1729,sodium
1730,generator
1731,congestive heart failure
1732,paediatric
1733,all-cause mortality
1734,global proteomics changes
1735,severe-end-stage
1736,iron deficiency
1737,descriptive
1738,referral
1739,hospital
1740,reproducible
1741,abnormal liver
1742,performers
1743,metabolic
1744,bnp
1745,end point
1746,procedure-related
1747,fractional shortening
1748,key genes
1749,aortic valve
1750,economic considerations
1751,nonpace
1752,perturbed
1753,vagal
1754,perturbed bone morphogenetic
1755,asymptomatic
1756,ventricles
1757,intervals
1758,primary end point
1759,years of age
1760,congestive
1761,imbalance
1762,restorative effects
1763,sparing
1764,amyloidotic
1765,compensatory hypertrophy
1766,sequence
1767,peripheral abnormalities
1768,summary
1769,uptitrations
1770,phenylephrine-induced
1771,left anterior
1772,follow
1773,outcomes
1774,predictors
1775,muscle
1776,subproteome
1777,beat-to-beat
1778,full length
1779,centrifugal-flow
1780,monitoring board
1781,contractile
1782,longitudinal systolic
1783,vena
1784,wall
1785,multiorgan
1786,cpr
1787,aerobic
1788,cost-effective
1789,interconnected
1790,age-dependent
1791,counterbalance
1792,end-diastolic pressure
1793,tac
1794,post-aac
1795,phosphocreatine
1796,telephone
1797,cardioverter-defibrillator
1798,attenuation
1799,distribution
1800,time-dependent
1801,body mass
1802,al
1803,young woman
1804,randomized trials
1805,levitated
1806,p70s6k
1807,attention-controlled
1808,transcription factor
1809,subspecialty
1810,inducing
1811,following
1812,lesion
1813,nuts
1814,beats
1815,mrnas
1816,developmental impairment
1817,muscular strength
1818,histone
1819,data extraction
1820,activating
1821,framework
1822,non-dnx
1823,fee-for-service
1824,interrelated
1825,pro-b-type
1826,driveline
1827,iron-deficient
1828,pathological changes
1829,severity
1830,edge-to-edge
1831,patients
1832,rats
1833,sickle
1834,underlying mechanism
1835,time frame
1836,anemia
1837,percutaneous
1838,longitudinal change
1839,peak
1840,swine
1841,circulation
1842,pump-exchange
1843,connected
1844,aha
1845,methods
1846,gas
1847,quality-adjusted survival
1848,30-day
1849,cohort
1850,spectrometry
1851,formalism
1852,co-primary
1853,endothelial
1854,measurement
1855,wall stiffness
1856,bolus
1857,systolic heart failure
1858,2-year study
1859,clinical
1860,refractory right
1861,elevation
1862,hart
1863,under the curve
1864,moderate
1865,clinician
1866,electrolytes
1867,myocardial perfusion
1868,systemic hypertension
1869,stroke
1870,residual
1871,weak grip
1872,counterparts
1873,load-corrected
1874,strain
1875,flow-mediated dilatation
1876,btes
1877,persistent
1878,improved hdl
1879,aortic pressure curve
1880,diuretic therapy
1881,blockade
1882,toxicity
1883,bhlh
1884,abnormal
1885,transthoracic
1886,high-dose
1887,event
1888,tolerance
1889,reporting
1890,calf muscle
1891,axis
1892,care management
1893,hfpsi
1894,burden
1895,rr
1896,mirnas
1897,inflammation
1898,myofiber
1899,point of care
1900,ring annuloplasty
1901,study
1902,cogeneration of nitrite
1903,limbs
1904,debilitating
1905,proportional hazard
1906,net-reclassification-improvement
1907,study-related
1908,small-molecule
1909,moderate-quality
1910,reperfusion therapy
1911,clear organic
1912,potassium level
1913,immunohistochemistry
1914,x-ray
1915,across-the-board
1916,studies
1917,pacemaker
1918,followed
